EARL RUSSELL: Open Payments
NPI 1447412275 · BROOKHAVEN, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$647 in 34 payments from 11 companies in 2025. Trend: 2023 $720 · 2024 $900 · 2025 $647
Food & beverage: $647
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $210 |
| GlaxoSmithKline, LLC. | 7 | $123 |
| Lilly USA, LLC | 4 | $73 |
| Novo Nordisk Inc | 3 | $53 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $40 |
| ABBVIE INC. | 2 | $40 |
| Exact Sciences Corporation | 2 | $36 |
| Averitas Pharma Inc. | 1 | $28 |
| KYOWA KIRIN, INC. | 1 | $24 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $14 |
Products named: FARXIGA, TRELEGY ELLIPTA, AIRSUPRA, MOUNJARO, Kerendia, QULIPTA, Ozempic, QUTENZA.
Industry payments across MS — which companies pay providers there.
